Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057.

Hartley JA, Hamaguchi A, Suggitt M, Gregson SJ, Thurston DE, Howard PW.

Invest New Drugs. 2012 Jun;30(3):950-8. doi: 10.1007/s10637-011-9647-z. Epub 2011 Mar 8.

PMID:
21384134
2.

SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

Hartley JA, Hamaguchi A, Coffils M, Martin CR, Suggitt M, Chen Z, Gregson SJ, Masterson LA, Tiberghien AC, Hartley JM, Pepper C, Lin TT, Fegan C, Thurston DE, Howard PW.

Cancer Res. 2010 Sep 1;70(17):6849-58. doi: 10.1158/0008-5472.CAN-10-0790. Epub 2010 Jul 26.

3.

Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: synthesis, DNA interaction, cytotoxicity and differential cellular localization.

Wells G, Suggitt M, Coffils M, Baig MA, Howard PW, Loadman PM, Hartley JA, Jenkins TC, Thurston DE.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2147-51. doi: 10.1016/j.bmcl.2008.01.083. Epub 2008 Jan 30.

PMID:
18280154
4.

The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.

Suggitt M, Cooper PA, Shnyder SD, Bibby MC.

Int J Oncol. 2006 Dec;29(6):1493-9.

PMID:
17088988
5.

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Suggitt M, Bibby MC.

Clin Cancer Res. 2005 Feb 1;11(3):971-81. Review.

6.

In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.

Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MF, Bradshaw TD.

Mol Cancer Ther. 2004 Dec;3(12):1565-75.

7.

Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.

Suggitt M, Swaine DJ, Pettit GR, Bibby MC.

Clin Cancer Res. 2004 Oct 1;10(19):6677-85.

8.

Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.

Suggitt M, Fearnley J, Swaine DJ, Volpato M, Phillips RM, Bibby MC, Loadman PM, Anderson D.

Teratog Carcinog Mutagen. 2003;Suppl 2:13-29.

PMID:
14691977

Supplemental Content

Loading ...
Support Center